Is Colossal profitable in 2026?

No. Colossal was pre-revenue at its Series C in January 2025, and by July 2026 Axios reported it has only 'some revenue' from selling conservation tech to the US government and UAE, while it has raised over $600M cumulative funding as of February 2026 to cover heavy burn.

Could AI replace Colossal Biosciences?

Partially. AI can commoditize Colossal's genome assembly and ancestral reconstruction work, which is why it spun that off into Astromech in April 2026 at a $2B valuation, but wet lab cloning, embryology, ancient DNA archives, and government relationships remain outside AI's reach.

Who owns Colossal Biosciences?

Colossal is privately held and venture backed. TWG Global, led by Mark Walter and Thomas Tull, led its $200M Series C that closed January 15, 2025 at a $10.2B post money valuation; founders George Church and Ben Lamm retain leadership roles.

Who is Colossal Biosciences' biggest competitor?

No direct commercial rival exists. Revive & Restore is a nonprofit doing similar genetic rescue work, and Mammoth Biosciences is a differently focused CRISPR diagnostics company despite the name overlap; Colossal is described as the dominant, most funded name in de-extinction.

How much money has Colossal Biosciences raised?

Cumulative funding exceeded $600M as of February 17, 2026 per Dallas Morning News, following a $200M Series C in January 2025 at $10.2B valuation and a $120M round in September 2025; as of July 20, 2026 it was reportedly in talks for a new round at $20B to $30B valuation.

When will Colossal actually bring back the woolly mammoth?

Colossal has publicly targeted mammoth embryos by the end of 2026 and a live birth in 2028, per its own July 2, 2026 statement, though the flagship product remains years away and unproven against that timeline.

United States · United States

Colossal

Genetic engineering company reviving extinct species and selling conservation and cloning tech.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from end of 2026 · Every call on the record Checkpoint: Target date for implantation-ready mammoth embryos

The call

Colossal holds unique science and government ties that AI cannot replicate, but its valuation still rests far more on mammoth-revival narrative than on confirmed recurring revenue.

Colossal uses ancient DNA and cloning technology to bring extinct animals like woolly mammoths back to life. The company is hard to copy because it owns rare DNA samples, has working lab equipment, and good relationships with governments, but AI can help with the computer parts of the work. The big problem is that the company is valued at 370 to 1100 times what it actually makes in money, burns through cash fast, has no steady paying customers yet, and won't deliver its first mammoth until 2028 or later. If a huge funding round it is trying to close actually happens, the company stays alive longer, but if it falls apart or the money comes at a lower value, the whole investment could fall apart quickly.

Why

AI pressure: AI genome-assembly and protein-modeling tools. AI can automate genome assembly and ancestral reconstruction, so Colossal spun that computational work into a separate company, Astromech. Could AI do the core job? Unlikely.

Bigger players: None apparent. No major biotech or tech giant has entered de-extinction or ancient-DNA reconstruction at Colossal's scale. Could a giant copy it? Probably.

What protects it. Its ancient-DNA archives, live wet-lab cloning work, and direct government contracts are hard for any AI tool or rival to copy.

What would change this call

Whether the reported $20B-$30B funding round closes by early 2027. Shows if narrative-driven fundraising can still outpace unproven revenue.
Whether implantation-ready mammoth embryos are achieved by end of 2026 as targeted. Tests if the flagship de-extinction timeline holds or slips.
Whether ViaGen or conservation-tech contracts disclose recurring revenue figures within a year. Indicates whether adjacent businesses can reduce dependence on the de-extinction narrative.

Key numbers

$10.2B valuation after Series C (2025-01-15)
Over $600M raised cumulatively (2026-02-17)
In talks for $20B-$30B valuation round (2026-07-20)

Named risks

Valuation running 370x to 1100x reported revenue with unproven repeating customer base. Severity: high
Dependence on a reported $20B to $30B fundraise still unconfirmed as of July 2026. Severity: high
Flagship mammoth product not due until 2028, years from monetization. Severity: medium
Scientific authenticity of dire wolf claims publicly disputed as of July 2026. Severity: medium
Heavy burn supporting 230 plus staff and new HQ funded mainly by narrative driven capital. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Revive and Restore	contesting	Nonprofit genetic rescue peer cited alongside Colossal by Scientific American, 2026-07-10
Mammoth Biosciences	contesting	Name overlap causes confusion but different focus on CRISPR diagnostics, not de-extinction

Questions people ask

Is Colossal profitable in 2026?: No. Colossal was pre-revenue at its Series C in January 2025, and by July 2026 Axios reported it has only 'some revenue' from selling conservation tech to the US government and UAE, while it has raised over $600M cumulative funding as of February 2026 to cover heavy burn.
Could AI replace Colossal Biosciences?: Partially. AI can commoditize Colossal's genome assembly and ancestral reconstruction work, which is why it spun that off into Astromech in April 2026 at a $2B valuation, but wet lab cloning, embryology, ancient DNA archives, and government relationships remain outside AI's reach.
Who owns Colossal Biosciences?: Colossal is privately held and venture backed. TWG Global, led by Mark Walter and Thomas Tull, led its $200M Series C that closed January 15, 2025 at a $10.2B post money valuation; founders George Church and Ben Lamm retain leadership roles.
Who is Colossal Biosciences' biggest competitor?: No direct commercial rival exists. Revive & Restore is a nonprofit doing similar genetic rescue work, and Mammoth Biosciences is a differently focused CRISPR diagnostics company despite the name overlap; Colossal is described as the dominant, most funded name in de-extinction.
How much money has Colossal Biosciences raised?: Cumulative funding exceeded $600M as of February 17, 2026 per Dallas Morning News, following a $200M Series C in January 2025 at $10.2B valuation and a $120M round in September 2025; as of July 20, 2026 it was reportedly in talks for a new round at $20B to $30B valuation.
When will Colossal actually bring back the woolly mammoth?: Colossal has publicly targeted mammoth embryos by the end of 2026 and a live birth in 2028, per its own July 2, 2026 statement, though the flagship product remains years away and unproven against that timeline.

Timeline

2026-07-20Reportedly in talks to raise new capital at $20B to $30B valuation, per Axios
2026-07-17Cloned four red wolves using new non-surgical mammalian cloning method
2026-04-07Spinout Astromech raises $40.5M, reaching $2B unicorn valuation
2026-02-17Toured new 55,000 sq ft Dallas HQ; headcount reported at 230 scientists
2025-11-04Closed acquisition of ViaGen Pets and Equine cloning business
2025-09-18Raised additional $120M round, pushing valuation past $10.3B
2025-01-15Closed $200M Series C led by TWG Global at $10.2B post money valuation
2025-01First dire wolves born (following an October 2024 birth), claimed as first large apex predator de-extinction
2023-06-11Announced $60M Series A, bringing total funding to $75M
2021-09-13Founded by George Church and Ben Lamm

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.